Apart from the above, our findings suggest that PET imaging of tau-protein using [11C]PBB3 biotracer is beneficial for differential diagnosis between AD and another neurodegenerative disorder with overlapping symptoms, such as frontotemporal lobar degeneration (FTLD), even in the early stages [28]. Here, MAPT is linked to Alzheimer disease.